| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 60/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product name | Dasatinib monohydrate |
| CAS NO | 863127-77-9 |
| Melting point | 203-213ºC |
| Boiling point | 417.3±45.0ºC |
| Density | 1.315 |
Dasatinib Monohydrate is an oral Bcr-Abl tyrosine kinase inhibitor (inhibits the "Philadelphia chromosome") and Src family tyrosine kinase inhibitor approved for first line use in patients with chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is being evaluated for use in numerous other cancers, including advanced prostate cance.
Chronic Myelogenous Leukemia (CML) Treatment: Used as a targeted therapy for patients with CML, particularly those who are resistant to or intolerant of other drugs like imatinib.
Acute Lymphoblastic Leukemia (ALL) Treatment: Dasatinib is employed in the treatment of Philadelphia chromosome-positive (Ph+) ALL, where it helps inhibit the abnormal BCR-ABL fusion protein that drives cancer growth.
Combination Therapy: Often administered in combination with other chemotherapeutics or targeted agents to enhance treatment outcomes in certain types of leukemia and blood disorders.
Clinical Trials: It is being investigated in clinical trials for the potential treatment of other malignancies, including solid tumors, where its ability to inhibit multiple tyrosine kinases shows promise.
Tyrosine Kinase Inhibition: Dasatinib is a potent inhibitor of multiple tyrosine kinases, including BCR-ABL, SRC family kinases, and certain receptor tyrosine kinases, thereby disrupting signaling pathways critical for cancer cell proliferation, survival, and migration.
Targeting Leukemia-Causing Mutations: In CML and Ph+ ALL, dasatinib specifically targets the mutated BCR-ABL protein, which is a key driver of the disease, leading to cancer cell death and disease control.
Modulation of Cellular Processes: By inhibiting tyrosine kinases, dasatinib modulates various cellular processes such as cell division, adhesion, and migration, ultimately impeding the growth and spread of cancer cells.
Selective Toxicity: Its mechanism of action allows for selectivity towards cancer cells, while sparing normal cells to a greater extent, though side effects can occur, especially at higher doses.
){kind=link}